Cover Image
Market Research Report


Published by Datamonitor Healthcare Product code 603960
Published Content info 46 Pages
Delivery time: 1-2 business days
Back to Top
Published: June 14, 2018 Content info: 46 Pages

PharmaVitae explores Teva's prescription pharmaceutical performance and outlook over 2017-27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.


  • Overview - Teva will look to build on the launches of Austedo and fremanezumab to counter the company's heavy debt burden and erosion of Copaxone by generics.
  • Key themes - [1] Growth will come from Teva's specialty medicines business [2] Teva is financially restricted by its large debt burden accrued through the acquisition of Actavis Generics [3] Copaxone sales will continue to fall as generics erode its market share.
  • Out to 2022 - Teva sales will shrink by $521m as Copaxone revenue diminishes.
  • Out to 2027 - Teva will begin to grow its revenue by adding $1.2bn due to fremanezumab and Austedo sales.
  • Pipeline - Teva is developing biosimilars of Rituxan and Herceptin.
  • Events - In May 2018, the FDA extended the approval date of fremanezumab to September 2018. Analysis structure
  • Explore and visualize revenue dynamics in Teva's portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.

Quarterly review

  • What were the major highlights from Teva's latest earnings call and quarterly performance?

Strategy analysis

  • How is Teva strategically poised out to 2027?
  • What are Teva's key strengths, weaknesses, opportunities, and threats?
  • What are Teva's key catalysts during the current year?

Portfolio analysis

  • Why will specific therapy areas experience the largest growth and decline?
  • What are the detailed competitive dynamics at play in Teva's important therapeutic markets?
  • How is Teva adapting strategically to internal and external headwinds in preceding quarters?

Facts and figures

  • What is Teva's forecasted sales performance out to 2027?
  • What is the revenue trajectory of Teva's current top 10 products out to 2027?
  • Which therapy areas will experience the largest growth and decline?
  • What are the portfolio weightings of Teva based on the lifecycle of its products?
Table of Contents
Product Code: DMKC0135934



  • Snapshot
  • Analysis structure

Q1 2018 REVIEW

  • Teva's outlook buoyed by new launches

Q4 2017 REVIEW

  • Teva will focus on higher-margin products to lessen debt concerns

Q3 2017 REVIEW

  • What were the highlights of Teva's Q3 earnings call?
  • Teva's debt burden deepens as credit rating is cut
  • Teva's strategy to reduce debt
  • Specialty pharmaceuticals pipeline update
  • Fremanezumab and Austedo launches will offset declines in Copaxone


  • Company background
  • Acquisition of Actavis Generics
  • Teva's involvement in scandals has reduced investor confidence
  • Teva's generics business has been hit by increased US price erosion
  • Previous CEO stepped down amid major company changes
  • Teva's SWOT analysis
  • Teva's key catalysts





  • Teva's prescription pharma sales outlook
  • Teva's regional pharma sales outlook
  • Teva's therapy area dynamics
  • Teva's growth drivers and resistors
  • Teva's lifecycle analysis
  • Teva's M&A strategy and history



  • Figure 1: Teva's prescription pharmaceutical sales ($m) and growth rate (%), 2014-27
  • Figure 2: Teva's therapy area dynamics, 2017-27
  • Figure 3: Teva's launch/core/expiry portfolio configuration, 2017-27


  • Table 1: Teva key product sales, Q1 2017-Q1 2018
  • Table 2: Sales of Teva's key specialty medicine products, Q4 2017 and full-year 2017
  • Table 3: Teva's sales by therapy area ($m), 2017-27
  • Table 4: Teva's prescription pharmaceutical sales by region ($m), 2017-27
  • Table 5: Teva's sales by therapy area ($m), 2017-27
  • Table 6: Teva's central nervous system portfolio sales, by product ($m), 2017-27
  • Table 7: Teva's respiratory portfolio sales, by product ($m), 2017-27
  • Table 8: Teva's key products, 2017-27
  • Table 9: Teva's sales by launch, core, and expiry portfolio ($m), 2017-27
  • Table 10: Teva's key merger and acquisition deals, 2006-18
Back to Top